-
Expert Opin Investig Drugs · Mar 2007
ReviewPTI-821: sustained-release oxycodone using gel-cap technology.
- Lynn R Webster.
- Lifetree Clinical Research and Pain Clinic, Salt Lake City, Utah, USA. lynnw@lifetreepain.com
- Expert Opin Investig Drugs. 2007 Mar 1;16(3):359-66.
AbstractPTI-821 is a long-acting formulation of oxycodone that is intended to deter abuse through its gel-cap technology. Produced by Pain Therapeutics in alliance with King Pharmaceuticals, PTI-821 is designed to provide strong pain relief with the intent of offering greater safety than is presently available from conventional controlled-release oxycodone products. This paper presents the available preliminary data on PTI-821 and discusses their potential clinical applications. The results of three pharmacokinetics studies and one Phase III, randomized, double-blind, clinical efficacy trial have been published in abstract form. PTI-821 has demonstrated a statistically significant difference from placebo (p < 0.05) in the efficacy study's primary end point: percentage decrease in pain scores. A further large, clinical study is in progress.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*,_underline_or**bold**. - Superscript can be denoted by
<sup>text</sup>and subscript<sub>text</sub>. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3., hyphens-or asterisks*. - Links can be included with:
[my link to pubmed](http://pubmed.com) - Images can be included with:
 - For footnotes use
[^1](This is a footnote.)inline. - Or use an inline reference
[^1]to refer to a longer footnote elseweher in the document[^1]: This is a long footnote..